Matinas BioPharma Holdings, Inc.

MTNB • Biotechnology

$0.18

▲ +0.00 (+0.55%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$1.17M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Crecimiento positivo de ingresos · 466.8%Nivel de deuda manejable · 0.28Liquidez saludable · 2.79Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 14 ago 2026, 12:40 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$0.18

Change0.55%

Shares Out6.41M

Market Cap$1.17M

Enterprise Value$410.93K

52W Range0.23 - 3.09

Beta1.75

P/E-0.16

P/B0.65

P/FCF-0.18

EV/EBITDA-0.06

EV/FCF-0.06

Price$0.18

Change0.55%

Shares Out6.41M

Market Cap$1.17M

Enterprise Value$410.93K

52W Range0.23 - 3.09

Beta1.75

P/E-0.16

P/B0.65

P/FCF-0.18

EV/EBITDA-0.06

EV/FCF-0.06

Earnings Yield-626.88%

FCF Yield-550.63%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.28

Current Ratio2.79

Quick Ratio2.79

Volume330.39K

Avg Volume5.23M

EPS Surprise1.02

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

95/100

Por qué este puntaje▼

Crecimiento positivo de ingresos · 466.8%Nivel de deuda manejable · 0.28Liquidez saludable · 2.79Rentabilidad débil

Analyst view

Analyst sentiment and price target

MTNB

Analyst sentiment

Based on 8 analyst votes · 2026-09-05

94/100

Bullish

Hold

Bearish

Resumen de la compañía

IPO: 7/21/2014

Industria: Biotechnology

P/B i: 0.65

Deuda / Patrimonio i: 0.28

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.28

Ratio corriente: 2.79

Ratio rápido: 2.79

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

⚠ 2 venta interna de alto volumens detectadas

STERN ADAM K

Transacción: 07/10/2026

VENTA

Cambio

-344,710

Precio

$0.35

Presentación

08/13/2026

Tipo

VENTA

STERN ADAM K

Transacción: 07/10/2026

COMPRA

Cambio

+344,710

Precio

$0.35

Presentación

08/13/2026

Tipo

COMPRA

Sanitam Partners LLC

Transacción: 06/10/2026

VENTA

Cambio

-4,798,636

Precio

$0.64

Presentación

08/13/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
STERN ADAM K	VENTA	-344,710	$0.35	07/10/2026	08/13/2026
STERN ADAM K	COMPRA	+344,710	$0.35	07/10/2026	08/13/2026
Sanitam Partners LLC	VENTA	-4,798,636	$0.64	06/10/2026	08/13/2026
Sanitam Partners LLC	VENTA	-1,406	$0.59	06/10/2026	08/13/2026
STERN ADAM K	COMPRA	+92,100	$0.64	10/31/2025	08/13/2026
STERN ADAM K	VENTA	-92,100	$0.64	10/31/2025	08/13/2026
STERN ADAM K	COMPRA	+265	$0.59	10/16/2025	08/13/2026
STERN ADAM K	COMPRA	+800,000	$0.64	10/16/2025	08/13/2026
Murphy Keith	COMPRA	+11,600	$0.59	04/30/2025	05/02/2025
Jabbour Jerome D	COMPRA	+70,100	$0.59	04/30/2025	05/02/2025
D An Evelyn	COMPRA	+11,600	$0.59	04/30/2025	05/02/2025
Smith Robin L	COMPRA	+11,600	$0.59	04/30/2025	05/02/2025
NEUGEBOREN EDWARD	COMPRA	+11,600	$0.59	04/30/2025	05/02/2025
Pembroke & Partners LLC	COMPRA	+492	$0.59	04/08/2025	04/10/2025
Pembroke & Partners LLC	COMPRA	+1,679,182	$0.64	04/08/2025	04/10/2025
EIDE ROBERT J	COMPRA	+492	$0.59	04/08/2025	04/10/2025
EIDE ROBERT J	COMPRA	+1,679,182	$0.64	04/08/2025	04/10/2025
Sanitam Partners LLC	COMPRA	+703	$0.59	04/08/2025	04/10/2025
Sanitam Partners LLC	COMPRA	+2,399,318	$0.64	04/08/2025	04/10/2025
STERN ADAM K	OTRO	+4,798,636	Not reported	02/13/2025	04/10/2025

Sobre la compañía

Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts. This sophisticated LNC delivery system leverages lipid nano-crystals to transport a diverse array of therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its primary experimental drug, LYPDISO, is a proprietary, prescription-grade omega-3 free fatty acid compound engineered to address cardiovascular and metabolic disorders. Matinas BioPharma is also advancing MAT2203, an orally administered version of amphotericin B. This candidate is currently in Phase II clinical trials, where it is being evaluated for its ability to prevent invasive fungal infections in patients undergoing immunosuppressive treatment. Furthermore, MAT2501, an oral formulation of the broad-spectrum aminoglycoside antibiotic amikacin, has successfully completed Phase I clinical trials. Its aim is to combat a spectrum of multidrug-resistant bacterial infections, such as non-tuberculous mycobacterium, multidrug-resistant gram-negative, and intracellular bacterial pathogens. The company actively engages in collaborations, including a research partnership with the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of Gilead's antiviral drug, remdesivir. Additionally, it has a feasibility collaboration with Genentech, Inc. focused on creating new oral drug formulations. Established in 2013, Matinas BioPharma maintains its corporate headquarters in Bedminster, New Jersey.

Fuente - Link

Competidores

ACXP ADIL ADXN BCLI CDIO HCWB IBO KTTA NRSN VYNE

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

BEDMINSTER, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on August 31, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders' equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years.

GlobeNewsWire

Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals

Will create publicly traded advanced clean energy company focused on modular carbon-free energy, green hydrogen, critical materials and industrial decarbonization

GlobeNewsWire

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance

BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders' equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company had stockholders' equity of $3.02 million and has had losses in the most recent five fiscal years ended December 31, 2025. As previously disclosed, the Company is also not in compliance with Section 1003(a)(iii) of the Company Guide requiring a company to have stockholders' equity of at least $6.0 million if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years. As of December 31, 2025, the Company had stockholders' equity of $4.83 million and has had losses in the most recent five fiscal years ended December 31, 2025. Due to its non-compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide, the Company is subject to the procedures and requirements of Section 1009 of the Company Guide.

GlobeNewsWire

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance

BEDMINSTER, N. J., June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the "Company") (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the "Company Guide") requiring a company to have stockholders' equity of at least $4.

Globe News Wire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-08	-1.3175	-0.3	1.0175
2026-03-31	-0.78	-0.3	0.48
2025-04-15	-0.78	-1.68	-0.9
2025-03-26	-0.78	-1.5	-0.72
2024-11-13	-1.05	-0.85	0.2
2024-08-14	-0.83333	-1	-0.16667
2024-05-09	-0.03	-1.5	-1.47
2024-03-27	-1.12503	-1.5	-0.37497
2023-11-08	-0.03	-1.5	-1.47
2023-08-09	-0.03	-1.5	-1.47
2023-05-10	-1.5	-1.5	0
2023-03-15	-1	-1	0